Top 10: Pharmaceutical Consulting Firms

Pharmaceutical companies in 2026 are navigating a more complex operating environment. R&D productivity pressures persist, and commercialisation pathways are becoming more fragmented. At the same time, evolving guidance from the U.S. Food and Drug Administration on AI and machine learning is reshaping how data-driven decisions are validated, governed and scaled.

Consulting firms in this space are expected to combine deep domain expertise with advanced analytics, regulatory awareness and implementation capability. Their focus has shifted away from standalone advisory services to supporting execution across clinical, commercial, and operational functions.

Healthcare Digital explores the Top 10 pharmaceutical consulting firms, from Capgemini and Huron to McKinsey and ZS.

ZS

Founded: 1983
Headquarters: Evanston, Illinois, US
Employees: ~15,000
Estimated revenue: ~US$2.7bn

ZS is a management consulting and technology firm that solves business challenges for pharmaceutical and biotech companies at every stage of the value chain – from drug discovery to clinical development, launch performance, market access, commercial strategy, patient engagement and more. The firm transforms ideas into impact by bringing together data, science, technology and human ingenuity to partner with companies to improve life and how we live it.

ZS makes the end-to-end connections that help clients discover breakthrough innovations and solve what seem like impossible challenges. The firm achieves success for clients by spanning boundaries to help build, scale and optimise their businesses for sustainable impact.

Its deep domain expertise includes forecasting, personalised engagement, field operations and patient-centric programmes, with a strong emphasis on driving sustained performance by redesigning recurring decisions as AI-native systems within value streams. Over 40-plus years in business, ZS has helped all top-50 global pharma companies create bold ideas and scalable executions using advanced analytics, AI and leading technologies.

McKinsey & Company

Founded: 1926
Headquarters: New York, US
Employees: ~38,000
Revenue: ~US$16bn

McKinsey integrates AI, analytics and strategy through its QuantumBlack unit.

Its pharmaceutical work spans R&D productivity, commercial transformation and enterprise analytics, with an increasing focus on scaling AI use cases from pilot to enterprise deployment across therapeutic areas.

The firm focuses on embedding data-driven decision-making into organisational structures, enabling initiatives to scale beyond pilot phases. Its global footprint supports transformation programs across multiple markets and therapeutic areas.

Accenture

Founded: 1989
Headquarters: Dublin, Ireland
Employees: ~786,000
Revenue: ~US$72.11bn

Accenture provides consulting and technology services across the pharmaceutical value chain, with a strong focus on large-scale transformation programmes that integrate AI, cloud and data platforms across global operations.

The firm is typically engaged for large, cross-functional programs requiring coordination across systems, geographies and business units, with a focus on delivering execution at scale.

Deloitte

Founded: 1845
Headquarters: London, UK
Employees: ~457,000
Revenue: ~US$70.5bn (FY2024)

Deloitte focuses on governance, compliance and enterprise transformation in regulated industries, helping pharmaceutical organisations scale AI and digital initiatives while aligning with evolving regulatory and risk frameworks.

This approach supports organisations working to balance innovation with compliance requirements across global markets.

IQVIA

Founded: 2016
Headquarters: Durham, North Carolina, US
Employees: ~93,000
Revenue: ~US$16.31bn (2024)

IQVIA combines proprietary healthcare datasets with analytics and consulting services, enabling evidence-based decision-making across patient journeys, market access and clinical development.

This foundation supports applications across patient journeys, market access and clinical research.

Boston Consulting Group (BCG)

Founded: 1963
Headquarters: Boston, Massachusetts, US
Employees: ~36,000
Revenue: ~US$14.4bn

BCG combines consulting with engineering and AI capabilities through BCG X. Its pharmaceutical work spans drug development, clinical trials and commercial analytics, with a focus on co-developing and deploying AI-driven solutions within client environments.

The firm’s co-creation model supports the development and implementation of solutions within client operating environments.

L.E.K. Consulting

Founded: 1983
Headquarters: London, UK
Employees: ~2,100
Revenue: ~US$1.2bn

L.E.K. Consulting focuses on pharmaceutical strategy, including portfolio optimisation, pricing and market access, with increasing integration of analytics to inform high-stakes investment and commercialisation decisions.

The firm is typically engaged at key decision points across the product life cycle where strategic clarity is required.

EY

Founded: 1989
Headquarters: London, UK
Employees: ~406,000
Revenue: ~US$53.2bn

EY supports pharmaceutical organisations with regulatory advisory, compliance and performance improvement, increasingly incorporating AI governance and digital transformation frameworks into its consulting approach.

The firm focuses on aligning transformation initiatives with financial performance and regulatory expectations.

Huron Consulting Group

Founded: 2002
Headquarters: Chicago, Illinois, US
Employees: ~7,400
Revenue: ~US$1.69bn

Huron works across research operations, clinical workflows and organisational performance, with a focus on improving efficiency and coordination in complex healthcare and academic environments.

Capgemini

Founded: 1967
Headquarters: Paris, France
Employees: ~420,000
Revenue: €25.41bn (US$29.92bn)

Capgemini applies an engineering-led approach across pharmaceutical manufacturing, supply chain and R&D operations, focusing on embedding AI and digital capabilities within production and operational systems.
This supports organisations scaling operational transformation within regulated environments.

The front-runners in pharmaceutical consulting

The role of pharmaceutical consulting is evolving alongside the industry it supports. As data, AI and regulatory expectations converge, successful consulting engagements are increasingly defined by their execution and the ability to operationalise insights within real-world environments.

Firms are being assessed on how effectively they combine domain expertise with analytics to drive measurable outcomes across clinical, commercial and patient-facing functions. In this context, scalability, decision intelligence and regulatory alignment are central to how consulting partners are evaluated.

As the industry evolves, pharmaceutical companies increasingly require both strategic direction and execution capabilities, with consulting partners expected to deliver across both to drive faster, more personalised and data-driven decision-making.